Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

305
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
305
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

207
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
207
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

145
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
145
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
167
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

182
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
182

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adipose Tissue Inflammation, Oxidative Stress, and Altered Adipogenesis Are Associated With Dyslipidemia in Obesity: A Multiomics Profiling Study.

Journal of the American Heart Association·2026
Same author

Lactic acid bacteria and endogenous ethanol mediate proton pump inhibitor-associated MASLD: a multicohort cross-sectional mediation analysis.

Gut microbes·2026
Same author

Macrophage-derived cathepsin B disrupts intestinal tight junctions through occludin degradation and promotes alcohol-associated liver disease.

Journal of hepatology·2026
Same author

Plasma Metabolite N-Formylmethionine Is Associated With Higher Blood Pressure in the Multiethnic HELIUS Cohort and Triggers Vascular Dysfunction.

Hypertension (Dallas, Tex. : 1979)·2025
Same author

Exploring the Role of the Gut Microbiome Across the Lifespan: Implications for Aging and Metabolic Disorders.

Journal of the Endocrine Society·2025
Same author

mAChR4 suppresses liver disease via GAP-induced antimicrobial immunity.

Nature·2025
Same journal

Accounting for approximation errors using surrogate-based parameter estimation of cardiac mechanics digital twins.

Computer methods and programs in biomedicine·2026
Same journal

Facial iPPG heatmap patterns based on period-aware autoencoder show association with carotid atherosclerosis towards non-contact hemodynamic assessment.

Computer methods and programs in biomedicine·2026
Same journal

Explainable machine learning models predict liver fibrosis risk and outcome in the general population: Development and multi-cohort external validation.

Computer methods and programs in biomedicine·2026
Same journal

Evaluation of surrogate endpoints for survival outcomes using the surrogate package in R.

Computer methods and programs in biomedicine·2026
Same journal

Relative spectral and frication-based descriptors as numerical indicators of place of articulation shifts in fricatives produced by Polish children.

Computer methods and programs in biomedicine·2026
Same journal

Leaflet resection improves valve expansion and hemodynamic performance in redo TAVI with balloon- and self-expanding transcatheter heart valve configurations.

Computer methods and programs in biomedicine·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2025

Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

23.5K

Does GLP-1 cause post-bariatric hypoglycemia: 'Computer says no'.

Ysanne M Pasveer1, Ömrüm Aydin2, Albert K Groen2

  • 1Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.

Computer Methods and Programs in Biomedicine
|September 26, 2024
PubMed
Summary
This summary is machine-generated.

Post-bariatric hypoglycemia (PBH) after gastric bypass surgery is not solely due to GLP-1. Rapid glucose absorption and altered insulin sensitivity are key factors identified by a mathematical model.

Keywords:
Bariatric surgeryGLP-1HypoglycemiaPhysiology-informed regularizationVirtual patients

More Related Videos

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

6.6K
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

9.4K

Related Experiment Videos

Last Updated: Jun 12, 2025

Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

23.5K
Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

6.6K
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

9.4K

Area of Science:

  • Metabolic surgery
  • Endocrinology
  • Computational modeling

Background:

  • Post-bariatric hypoglycemia (PBH) is a complication following Roux-en-Y Gastric Bypass (RYGB).
  • Elevated glucagon-like peptide-1 (GLP-1) levels have been hypothesized as the primary cause of PBH.

Purpose of the Study:

  • To investigate the role of GLP-1 in PBH using a physiology-based mathematical model.
  • To identify the underlying mechanisms contributing to PBH after RYGB surgery.

Main Methods:

  • Adaptation of the Eindhoven Diabetes Simulator (EDES) model to incorporate GLP-1 effects on insulin secretion.
  • Parameter sensitivity analysis to pinpoint PBH-inducing factors.
  • Creation of virtual patient models based on the HypoBaria study cohort (n=63) pre- and post-surgery.

Main Results:

  • The model accurately simulated glycemic excursions in a heterogeneous study population.
  • GLP-1 stimulated insulin secretion alone was insufficient to cause PBH.
  • Increased gastrointestinal transit speed leading to rapid glucose absorption was identified as a primary driver of postprandial dips.
  • A combination of accelerated glucose absorption and varying insulin sensitivity contributes to PBH.

Conclusions:

  • PBH may emerge over time due to an initial rapid improvement in insulin sensitivity post-surgery, followed by a gradual decline.
  • Mathematical modeling provides insights into the complex pathophysiology of PBH.